Johnson & Johnson (JNJ) Q1 Earnings and Revenues Beat Estimates

Core Insights - Johnson & Johnson (JNJ) reported quarterly earnings of $2.77 per share, exceeding the Zacks Consensus Estimate of $2.57 per share, and showing an increase from $2.71 per share a year ago, resulting in an earnings surprise of 7.78% [1] - The company achieved revenues of $21.89 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.26% and up from $21.38 billion year-over-year [2] - Johnson & Johnson has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The future stock price movement will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings performance [3] - Current consensus EPS estimate for the upcoming quarter is $2.67 on revenues of $22.61 billion, and for the current fiscal year, it is $10.54 on revenues of $90.22 billion [7] Industry Context - The Large Cap Pharmaceuticals industry, to which Johnson & Johnson belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] Competitor Insights - Merck (MRK), another company in the same industry, is expected to report quarterly earnings of $2.16 per share, reflecting a year-over-year increase of 4.4%, with revenues anticipated to be $15.48 billion, down 1.9% from the previous year [9][10]